Induction immunosuppression for combined heart-lung transplantation

Area of Science:

• Transplantation immunology
• Cardiothoracic surgery

Background:

• Limited research exists on induction immunosuppression strategies for combined heart-lung transplantation (HLTx).
• Optimizing immunosuppression is crucial for post-transplant outcomes in HLTx recipients.

Purpose of the Study:

• To evaluate the impact of induction immunosuppression on survival and acute rejection in adult and adolescent HLTx recipients.
• To determine if contemporary induction agents offer a survival benefit in combined heart-lung transplantation.

Main Methods:

• Retrospective analysis of the United Network for Organ Sharing database (2000-2013).
• Inclusion of adult (≥18 years) and adolescent (≥12 to <18 years) patients undergoing combined HLTx.
• Application of univariate and multivariate Cox proportional hazards models to assess mortality and rejection episodes.

Main Results:

• No significant differences in post-HLTx mortality were observed across various induction immunosuppression strategies, including basiliximab, thymoglobulin/antilymphocyte globulin (ALG)/antithymocyte globulin (ATG), and alemtuzumab, compared to no induction.
• Multivariate analysis, adjusted for corticosteroid use, confirmed no survival benefit associated with any tested induction immunosuppression agent.
• No differences in treated acute rejection episodes were found based on the type of induction immunosuppression used.

Conclusions:

• Contemporary induction immunosuppression agents do not appear to enhance survival following combined heart-lung transplantation.
• Current induction protocols may not be essential for improving long-term outcomes in HLTx patients.
• Further research may be needed to identify optimal immunosuppression strategies for this patient population.